Wild Horseshoe Crab Welfare and Biomedical Harvest

Horseshoe crabs are harvested for their blood's unique clotting properties used in medical testing, with welfare concerns now driving alternatives.

Key Facts

Horseshoe crab blood contains limulus amebocyte lysate (LAL) that detects bacterial endotoxins
LAL testing is required for all injectable and implantable medical devices worldwide
Approximately 600,000 horseshoe crabs are bled annually in the US with 15-30% mortality after release
Rfc C (recombinant Factor C) is a validated synthetic alternative to LAL in many applications
Horseshoe crabs are critical food for migratory shorebirds including Red Knots that time migrations to their eggs
Delaware Bay hosts the world's largest horseshoe crab aggregation for spawning
The FDA has approved rFC for pharmaceutical testing but its use remains limited due to regulatory inertia

Welfare Considerations

Horseshoe crab bleeding involves capture, transport to facilities, drainage of up to 30% of blood volume, and return to the sea. Stress during the process and blood loss cause measurable physiological impacts, with significant mortality among returned animals especially females. The existence of validated synthetic alternatives that eliminate this welfare harm makes the continued large-scale bleeding of horseshoe crabs increasingly difficult to justify from a welfare standpoint.

What You Can Do

Advocate for regulatory acceptance and industry adoption of recombinant Factor C as an LAL alternative
Support pharmaceutical companies that have transitioned to rFC alternatives
Learn about horseshoe crab ecology and their critical role in shorebird migration systems
Donate to conservation organizations monitoring horseshoe crab populations and shorebird dependencies
Engage with medical device and pharmaceutical companies on transitioning away from LAL testing
Support research into other synthetic alternatives to animal-derived biological testing reagents